Reports - Point Of Care Molecular Diagnostics Market
HealthcarePoint Of Care Molecular Diagnostics Market
Point Of Care Molecular Diagnostics Market Size and Share Analysis for 2035 by Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Hybridization Technologies (Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), DNA Sequencing, Microarrays, Other Technologies) by Application Type (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other Applications) by End-Use (Decentralized Labs, Hospitals, Home-care, Assisted Living Healthcare Facilities, Research Institutes, Other End Uses) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Point Of Care Molecular Diagnostics Market - Segment Analysis
1. Overview
2. Global Point Of Care Molecular Diagnostics Market, 2021 - 2035 (USD Million)
3. Global Point Of Care Molecular Diagnostics Market - by Technology
3.1. By Polymerase Chain Reaction (PCR)
3.2. By Isothermal Nucleic Acid Amplification Technology (INAAT)
3.3. By Hybridization Technologies (Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH)
3.4. By DNA Sequencing
3.5. By Microarrays
3.6. By Other Technologies
4. Global Point Of Care Molecular Diagnostics Market - by Application Type
4.1. By Infectious Diseases
4.2. By Oncology
4.3. By Hematology
4.4. By Prenatal Testing
4.5. By Endocrinology
4.6. By Other Applications
5. Global Point Of Care Molecular Diagnostics Market - by End-Use
5.1. By Decentralized Labs
5.2. By Hospitals
5.3. By Home-care
5.4. By Assisted Living Healthcare Facilities
5.5. By Research Institutes
5.6. By Other End Uses
6. Global Point Of Care Molecular Diagnostics Market - by region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa
7. Market comparative analysis
Chapter 4 North America Point Of Care Molecular Diagnostics Market - Segment Analysis
1. Overview
2. North America Point Of Care Molecular Diagnostics Market, 2021 - 2035 (USD Million)
3. North America Point Of Care Molecular Diagnostics Market - by Technology
3.1. By Polymerase Chain Reaction (PCR)
3.2. By Isothermal Nucleic Acid Amplification Technology (INAAT)
3.3. By Hybridization Technologies (Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH)
3.4. By DNA Sequencing
3.5. By Microarrays
3.6. By Other Technologies
4. North America Point Of Care Molecular Diagnostics Market - by Application Type
4.1. By Infectious Diseases
4.2. By Oncology
4.3. By Hematology
4.4. By Prenatal Testing
4.5. By Endocrinology
4.6. By Other Applications
5. North America Point Of Care Molecular Diagnostics Market - by End-Use
5.1. By Decentralized Labs
5.2. By Hospitals
5.3. By Home-care
5.4. By Assisted Living Healthcare Facilities
5.5. By Research Institutes
5.6. By Other End Uses
Chapter 5 Europe Point Of Care Molecular Diagnostics Market - Segment Analysis
1. Overview
2. Europe Point Of Care Molecular Diagnostics Market, 2021 - 2035 (USD Million)
3. Europe Point Of Care Molecular Diagnostics Market - by Technology
3.1. By Polymerase Chain Reaction (PCR)
3.2. By Isothermal Nucleic Acid Amplification Technology (INAAT)
3.3. By Hybridization Technologies (Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH)
3.4. By DNA Sequencing
3.5. By Microarrays
3.6. By Other Technologies
4. Europe Point Of Care Molecular Diagnostics Market - by Application Type
4.1. By Infectious Diseases
4.2. By Oncology
4.3. By Hematology
4.4. By Prenatal Testing
4.5. By Endocrinology
4.6. By Other Applications
5. Europe Point Of Care Molecular Diagnostics Market - by End-Use
5.1. By Decentralized Labs
5.2. By Hospitals
5.3. By Home-care
5.4. By Assisted Living Healthcare Facilities
5.5. By Research Institutes
5.6. By Other End Uses
Chapter 6 Asia Pacific Point Of Care Molecular Diagnostics Market - Segment Analysis
1. Overview
2. Asia Pacific Point Of Care Molecular Diagnostics Market, 2021 - 2035 (USD Million)
3. Asia Pacific Point Of Care Molecular Diagnostics Market - by Technology
3.1. By Polymerase Chain Reaction (PCR)
3.2. By Isothermal Nucleic Acid Amplification Technology (INAAT)
3.3. By Hybridization Technologies (Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH)
3.4. By DNA Sequencing
3.5. By Microarrays
3.6. By Other Technologies
4. Asia Pacific Point Of Care Molecular Diagnostics Market - by Application Type
4.1. By Infectious Diseases
4.2. By Oncology
4.3. By Hematology
4.4. By Prenatal Testing
4.5. By Endocrinology
4.6. By Other Applications
5. Asia Pacific Point Of Care Molecular Diagnostics Market - by End-Use
5.1. By Decentralized Labs
5.2. By Hospitals
5.3. By Home-care
5.4. By Assisted Living Healthcare Facilities
5.5. By Research Institutes
5.6. By Other End Uses
Chapter 7 Latin America Point Of Care Molecular Diagnostics Market - Segment Analysis
1. Overview
2. Latin America Point Of Care Molecular Diagnostics Market, 2021 - 2035 (USD Million)
3. Latin America Point Of Care Molecular Diagnostics Market - by Technology
3.1. By Polymerase Chain Reaction (PCR)
3.2. By Isothermal Nucleic Acid Amplification Technology (INAAT)
3.3. By Hybridization Technologies (Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH)
3.4. By DNA Sequencing
3.5. By Microarrays
3.6. By Other Technologies
4. Latin America Point Of Care Molecular Diagnostics Market - by Application Type
4.1. By Infectious Diseases
4.2. By Oncology
4.3. By Hematology
4.4. By Prenatal Testing
4.5. By Endocrinology
4.6. By Other Applications
5. Latin America Point Of Care Molecular Diagnostics Market - by End-Use
5.1. By Decentralized Labs
5.2. By Hospitals
5.3. By Home-care
5.4. By Assisted Living Healthcare Facilities
5.5. By Research Institutes
5.6. By Other End Uses
Chapter 8 Middle East & Africa Point Of Care Molecular Diagnostics Market - Segment Analysis
1. Overview
2. Middle East & Africa Point Of Care Molecular Diagnostics Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Point Of Care Molecular Diagnostics Market - by Technology
3.1. By Polymerase Chain Reaction (PCR)
3.2. By Isothermal Nucleic Acid Amplification Technology (INAAT)
3.3. By Hybridization Technologies (Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH)
3.4. By DNA Sequencing
3.5. By Microarrays
3.6. By Other Technologies
4. Middle East & Africa Point Of Care Molecular Diagnostics Market - by Application Type
4.1. By Infectious Diseases
4.2. By Oncology
4.3. By Hematology
4.4. By Prenatal Testing
4.5. By Endocrinology
4.6. By Other Applications
5. Middle East & Africa Point Of Care Molecular Diagnostics Market - by End-Use
5.1. By Decentralized Labs
5.2. By Hospitals
5.3. By Home-care
5.4. By Assisted Living Healthcare Facilities
5.5. By Research Institutes
5.6. By Other End Uses
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Abbott Laboratories (U.S.)
2. Bayer AG (Germany)
3. F. Hoffmann-La Roche AG (Switzerland)
4. Nova Biomedical (U.S.)
5. QIAGEN (Germany)
6. Nipro Diagnostics (Japan)
7. Danaher (U.S.)
8. Bio-Rad Laboratories Inc. (U.S.)
9. bioMérieux (France)
10. Agilent Technologies Inc. (U.S.)
11. Abaxis (U.S.)
12. OraSure Technologies (U.S.)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By